Hours

Minutes

Seconds

-40%

on all subscriptions*

Enjoy this offer

* See conditions under "Our services"

ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
11/06/26	0.1905 p	+5.83%	15,108,346
10/06/26	0.1800 p	0.00%	3,327,371
09/06/26	0.1800 p	0.00%	92,433
08/06/26	0.1800 p	-2.70%	6,441,816
05/06/26	0.1850 p	0.00%	4,560,465

Delayed Quote London S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - London S.E. Other stock markets 19:35:07 11/06/2026 +04			5-day change	1st Jan Change
0.1905 ^GBX	+5.83%		+2.97%	-43.13%

06-02	ValiRx Completes Oncology Assets Evaluation Deal with Stingray Bio	MT
05-27	ValiRx subsidiary Cytolytix granted "core" European patent	AN

Market Cap	2.49M 3.32M 2.88M 2.66M 4.65M 318M 4.75M 31.68M 12.26M 153M 12.46M 12.19M 533M	P/E Ratio 2023	-2.94x	P/E Ratio 2024	-0.53x
Enterprise Value	944K 1.26M 1.09M 1.01M 1.76M 121M 1.8M 12.02M 4.65M 58.13M 4.73M 4.63M 202M	EV / Sales 2023	612,941,875x	EV / Sales 2024	27,264,249x
Free-Float	93.43%	Yield 2023 *	-	Yield 2024	-

06-02	ValiRx Completes Oncology Assets Evaluation Deal with Stingray Bio	MT
05-27	ValiRx subsidiary Cytolytix granted "core" European patent	AN
05-27	ValiRx Unit Wins European Patent for Anti-Cancer Peptide Patent	MT
05-21	ValiRx Raises Funds via Retail Offering	MT
05-18	ValiRx to Raise Funds via Retail Offer	MT
05-15	IAG launches new buyback; Forgent settles legal case	AN
05-15	WINNERS & LOSERS: Kendrick drilling results; Blackbird new approach	AN
05-15	ValiRx Seeks to Raise Over GBP1 Million via Share Issue	MT
05-14	WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down	AN
03-31	ValiRx PLC Announces Change Of Registered Office	CI
03-03	ValiRx establishes veterinary oncology-focused subsidiary	AN
03-02	ValiRx Forms Veterinary Oncology Unit	MT
03-02	ValiRx plc Sets Up Wholly Owned Subsidiary ValiRx Animal Health Limited	CI

24/03/25	ValiRx PLC - Director Disclosure Update	AQ
19/09/24	ValiRx plc - Inaphaea Evaluation and Commercial Use Agreement	AQ
06/12/23	ValiRx strikes deal with Ambrose Healthcare to license late-stage cancer treatment	AQ
01/02/23	ValiRx signals launch of new strategy with Nottingham laboratories	AQ
16/12/22	ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment	AQ

ValiRx plc Stock

Stocks

VAL

GB00BLH13C52

Biotechnology & Medical Research

Valuation: ValiRx plc

Chart: ValiRx plc

Latest news : ValiRx plc

Press Releases: ValiRx plc

Quotes and Performance

Course Extremes

Managers and Directors: ValiRx plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+5.83%
1 week	+2.97%
Current month	-2.31%
1 month	-28.11%
3 months	-37.54%
6 months	-47.81%
Current year	-43.13%

1 week	0.17	0.19
1 month	0.17	0.29
Current year	0.17	0.48
1 year	0.17	0.88
3 years	0.17	15
5 years	0.17	65
10 years	0.17	1,436.25

Manager	Title	Age	Since
Mark Eccleston CEO	Chief Executive Officer	55	12/08/2024
Gerald Desler DFI	Director of Finance/CFO	81	-
Michelle Barnard CTO	Chief Tech/Sci/R&D Officer	-	27/03/2025

Director	Title	Age	Since
Gerald Desler BRD	Director/Board Member	81	01/09/2006
Martin Gouldstone CHM	Chairman	59	25/07/2024
Mark Eccleston BRD	Director/Board Member	55	12/08/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-04	Mark Eccleston	Buy	Chief Executive Officer	1,000,000	0.1346%
18/10/22	Stella Panu	Free	Director	75,000	0.0832%
18/10/22	Stella Panu	Free	Director	75,000	0.0832%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALIRX PLC	+5.83%	+2.97%	-57.67%	-97.91%	1.85M
ARGENX SE	+1.65%	+6.42%	+53.16%	+109.62%	54.82B
WUXI APPTEC CO., LTD.	+0.03%	-1.80%	+49.57%	+43.94%	43.27B
BIONTECH SE	+3.88%	+0.07%	-14.99%	-18.34%	21.79B
INSMED INCORPORATED	+5.89%	-7.03%	-0.44%	+400.23%	19.92B
WUXI BIOLOGICS (CAYMAN) INC.	+0.81%	-8.38%	+12.77%	-33.24%	15.67B
GENMAB A/S	+0.53%	+2.08%	+8.89%	-40.13%	15.26B
EXELIXIS, INC.	+2.49%	+2.54%	+29.92%	+181.95%	13.22B
PHARMAESSENTIA CORPORATION	-5.27%	+3.89%	+90.88%	+208.02%	11.58B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.74%	-1.05%	+12.88%	-	11.94B
Average	+1.41%	-1.05%	+18.50%	+83.79%	20.75B
Weighted average by Cap.	+1.29%	+1.16%	+32.11%	+98.00%

	2023	2024
Net sales	0.01 0.01 0.01 0.01 0.02 1.23 0.02 0.12 0.05 0.59 0.05 0.05 2.06	0.05 0.07 0.06 0.05 0.09 6.36 0.09 0.63 0.25 3.07 0.25 0.24 10.66
Net income	-2.04M -2.72M -2.36M -2.17M -3.81M -260M -3.89M -25.94M -10.04M -125M -10.21M -9.99M -436M	-1.92M -2.56M -2.22M -2.04M -3.58M -245M -3.65M -24.39M -9.44M -118M -9.59M -9.39M -410M
Net Debt	-153K -204K -177K -163K -285K -19.5M -291K -1.94M -752K -9.4M -764K -748K -32.68M	-1.54M -2.06M -1.79M -1.65M -2.89M -197M -2.95M -19.66M -7.61M -95.08M -7.73M -7.57M -331M